Posts tagged as:

IHE

The U.S.’s growing aging population has made pharmaceutical spending a significant portion of our nation’s GDP, and has also affected job creation and stock market appreciation. This spike in national interest in healthcare has also occurred on Wall Street, where investors are embracing this market and its attractive growth potential. While there are some potential roadblocks and government decisions that could curb the industry’s growth, there are a few standout funds in the pharmaceutical sector battling for investor attention: PowerShares Dynamic Pharmaceuticals Portfolio (PJP, B-), iShares Dow Jones US Pharmaceuticals Index Fund  (IHE, C+) and SPDR S&P Pharmaceuticals  (XPH, B-) [Download How To Pick The Right ETF Every Time].

[click to continue…]

{ Comments on this entry are closed }

As 2012 draws to a close, we’ve been recapping some of the best and worst ETF performers over the past year. Today, we’re taking a look back at the biggest winners and losers of the previous year–2011– to see how they followed up their impressive (or depressing) years in 2012. 

Many of the asset classes that surged in 2011 posted another stellar year in 2012, and many of those that struggled mightily in 2011 continued their freefall in 2012. Of course, there are some that dramatically reversed course in 2012. Below, we highlight the ETFs profiled last year in our 10 Equity ETFs That Surged In 2011 and 10 Worst ETF Performers Of 2011 with an update on the 2012 performance [for more ETF ideas, sign up for the free ETFdb newsletter]:

[click to continue…]

{ Comments on this entry are closed }

While some American’s were elated with Obama’s re-election, Wall Street made it quite clear who it had voted for as markets took a sharp nosedive in a post-election sell off immediately following the President’s victory. To many investors, Obama’s re-election has placed looming concerns over the Fiscal Cliff to the forefront, as the automatic round of […]

{ Comments on this entry are closed }

With the 2012 presidential elections only a few days away, folks in Washington, Wall Street and Main Street are gearing up to see who will occupy the coveted Oval Office come January. As with any election, there are, of course, those who are still raising their metaphorical pitchforks, slinging mud at the two candidates, and […]

{ Comments on this entry are closed }

Stock markets logged another session in green territory as upbeat earnings results collided with optimistic speculation that Spain would soon request bailout assistance. Positive economic data at home also helped to restore investors’ confidence in the recovery; industrial production in September increased by 0.4%, marking a major improvement from the previous month’s reading, which showed […]

{ Comments on this entry are closed }

This time last year, investors were generally thrilled with the performances of their portfolios, which had continued to bounce back nicely from the devastating recession that hit in 2008. Unfortunately, few are feeling the same sense of accomplishment as 2011 draws to a close; this year has been frustrating in that a few large, swift […]

{ Comments on this entry are closed }

RBS rolled out its fifth ETN this week, debuting a product that offers exposure to the world’s largest pharmaceutical firms. The new Global Big Pharma ETN (DRGS) will seek to replicate the NYSE Arca Equal Weighted Pharmaceutical Total Return Index, a benchmark that consists of equal allocations to about 16 different companies involved in various […]

{ Comments on this entry are closed }

Pharmaceutical companies have long been popular investments as they offer relatively inelastic products as well as strong dividend yields that give both growth and value investors something to buy into. As far as the ETF world is concerned, there are four products that allow investors to gain access to this investment class. But with the […]

{ Comments on this entry are closed }

Run For The Hills!

by on August 6, 2011

This past week was one of the worst the markets have seen since the crash in 2008. Lawmakers in Washington came to a consensus regarding the debt-ceiling, voting to raise the limit on our nation’s already towering deficit. Investor sentiment was pessimistic nonetheless and equity markets sold off even after the debt-drama appeared to be […]

{ Comments on this entry are closed }

Roller Coaster Ride Continues

by on August 3, 2011

Monday was yet another down day for Wall Street as stocks started the week in red territory given the anticipation surrounding the debt-ceiling negotiations. Even after lawmakers in Washington passed the debt-deal on Tuesday, equities still tanked in afternoon trading as investors went into a selling-frenzy. Persistent uncertainty and broad-based weakness continue to pave the […]

{ Comments on this entry are closed }

Equities Poised To Pop

by on August 1, 2011

Investors went along for a downhill  ride last week as debt woes plagued Wall Street, sending the S&P 500 lower by nearly 4% for the week. Corporate earnings were mostly surprises to the upside, but equities failed to stage a meaningful comeback since investors were more concerned with the debt ceiling drama at home. As […]

{ Comments on this entry are closed }

The last week of April was a pretty solid one for markets as equities rose broadly throughout the week to finish the month at fresh highs. While a number of earnings reports were key to the positive investor sentiment, arugably the biggest news story of the week came from the Federal Reserve meeting on Wednesday. In […]

{ Comments on this entry are closed }